Business
Avivagen Secures Approval for Use of OxC-beta™ Livestock in Brazil and Signs Distribution Agreement
Avivagen Secures Approval for Use of OxC-beta™ Livestock in Brazil and Signs Distribution Agreement.
About this update from Avivagen, Inc.
[{"type":"text","content":"\nAvivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”) a life sciences corporation focused on developing and commercializing immune-system improving products for livestock, companion animal and human applications, is pleased to announce that it has received approval from The Ministry of Agriculture-Feed Additives Division for the immediate use of OxC-beta™ Livestock in poultry, swine and cattle (beef and dairy) in Brazil. With regulatory approval secured, Avivagen has also signed a distribution agreement with established São Paulo-based Look Chemicals Importacao E Exportacao LTDA for the use of OxC-beta™ Livestock in poultry and swine.\n\n\n“We are very excited to secure approval for the use of OxC-beta™ Livestock in Brazil, one of the world’s largest livestock feed markets and an important exporter to many key regions worldwide,” says Kym Anthony, Chief Executive Officer, Avivagen. “With a local distribution agreement already in place with well-regarded Look Chemicals we expect to see quick adoption of OxC-beta™ Livestock in the South American market, with Brazil becoming an important part of Avivagen’s continued growth worldwide.”\n\n\nBrazil is the world’s third largest production market, producing 69mm tonnes of livestock feed each year, and a key exporter to regions such as Europe that have previously implemented bans against the use of antibiotics in livestock feedi. With the addition of regulatory approval in Brazil, OxC-beta™ Livestock is now approved for use in nine markets worldwide, including the United States, Mexico, New Zealand, Australia, Taiwan, Thailand, Malaysia and the Philippines.\n\n\nAbout Avivagen\n\n\nAvivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen...